Whether gosatuzumab (Tudavi) has been included in medical insurance and the latest policy updates

Gosatuzumab (Trodelvy), as an innovative antibody drug conjugate (ADC), has shown good efficacy in the treatment of multiple refractory solid tumors. The drug has been successfully launched in China recently, bringing new treatment options to patients with breast cancer and other diseases. Although it has been on the market for a short time, gosatuzumab has received widespread clinical attention due to its precise targeting effect and good efficacy.

At present, gosatuzumab has not been included in my country's national medical insurance directory. This means that patients need to bear all the cost of the medicine when purchasing, which costs approximately more than 8,000 yuan per box. Due to the higher price, some patients may face greater financial pressure. The specific purchase price may vary by region and hospital. Patients are advised to go to the local hospital pharmacy for detailed consultation to obtain the most accurate cost information.

Relevant departments and pharmaceutical companies are actively promoting the inclusion of gosatuzumab in medical insurance. With the accumulation of more clinical data and the widespread use of the drug, it is expected to be included in the medical insurance catalog in the future, reducing the financial burden for more patients. Adjustments to medical insurance policies usually require drug evaluation, price negotiation, and policy approval. There is a certain degree of uncertainty in the timing, but the overall trend is to support the inclusion of innovative drugs in the insurance system.

In short, as a new anti-cancer drug with important clinical value, gosatuzumab is not yet included in medical insurance, but its launch provides patients with new treatment options. When taking medication, patients should consider their own financial situation and doctor's advice to plan a reasonable treatment plan. At the same time, pay attention to the latest developments in medical insurance policies, and look forward to future medical insurance coverage benefiting more patients and promoting the popularization and development of anti-cancer treatment.

Reference materials:https://www.drugs.com